Full-Time
Posted on 2/19/2025
Develops immunotherapies for cell therapy
$140k - $180kAnnually
Senior, Expert
San Carlos, CA, USA
The job is onsite in Redwood City, CA.
You match the following Arcellx's candidate preferences
Employers are more likely to interview you if you match these preferences:
Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary immunotherapy products and has a business model that includes research, development, and commercialization, generating revenue through partnerships and licensing agreements. The main goal of Arcellx is to meet unmet medical needs by creating safe and effective treatment options.
Company Size
51-200
Company Stage
IPO
Total Funding
$194.5M
Headquarters
Gaithersburg, Maryland
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Work Hours
401(k) Company Match
Fully-Paid Parental Leave
Tuition Reimbursement
Relocation Assistance
REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody
REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody
Arcellx, Inc. (NASDAQ:ACLX) just released its full-year report and things are looking bullish.
Biotech Arcellx promotes Myesha Lacy to chief investor and comms officer | PR Week
The partnership with Arcellx was recently expanded to develop CART-ddBCMA to treat lymphomas.